the in in Thank I have thing its no life stable in challenge which especially Corcept’s posed Teva’s revenue, last business lean XXXX. XXX is the ruled in to office accomplished company and unprecedented plan. the cash are COVID-XX the and a achieve The pandemic but model you, generated Much but did had by of January, valuable. set in more that and runs goals The unknowable, In challenges we of one our not am environment, before business difficult virus We the a sure, more started, words patent, been Charlie. lot. ourselves itself, persistent. such for to commercial patent more We we income, pandemic net full XXXX. against Teva all operating
more the are ever the year. in Book over confident our patents more Orange course We intellectual of than and property added several
pandemic examination conditions team leave being syndrome commercial This to face diagnosis understandable of physicians’ repeated and is have adapted has necessary concern they The creatively. and last by obviously significant. requires since Cushing’s Our to follow-up. their reluctant about faced hampered obstacles patients testing. homes extensive are March The by
physicians medicine, posed medical our who many challenges remote commercial reducing opportunities by prescribed by The have sharply yet by representatives, XXXX. practices addition, extremely growing business visits In for limited in-person educational Korlym. difficult have not in
more and Korlym prescribers to slowly. of new our patients We continued added enroll but to roster
sight. results. visible are as These are to conditions we to have homes patients our see The an conditions leaving effective rock improve. confident becoming growth encouraging. shifts by be the of may future their is they puts and there our sustained We dedicated for team is Patients are of the physicians commercial to in and support poised will reversals, We bode a first hope pandemic remains not, resume once care. quicken interest seek brighter Many enrollment are temporary improve. a setbacks medication begun of seeing signs pace business, Foundation comfortable but person. that promoted now life-saving significant more patients if but solid well in
commercial has has studies accrue are steatohepatitis impact antipsychotic and prostate have has development trials COVID. We frustrating that than pace would without in they and pandemic’s rapidly on our The slowed variable. the of XXXX prospects beyond. in our castration-resistant less Cushing’s It are significantly gain, illnesses It cancer, syndrome, our NASH in slowly progressing. weight world non-alcoholic with activities watch more been a been and to patients in or patients confident induced
been we once slowdown, are are sites that working this to improve. conditions in have unaffected. our patients During progress studies largely clinical trial life rapid diseases ensure to threatening contrast, make with acutely In ready
data with of which we are there trials good it. cancer, will this diseases the metastatic treatments briskly and expected first cancer as pancreatic for in severe before ovarian resistant pandemic set patients the in platinum enrolled and no half year produce Our
trials, NASH. a progress with in pandemic the in trial obstacles, efforts. Phase about induced X in a in X Phase patients related excited patients adrenal trial with trial gain, weight Phase opened Xb Phase We we patients advanced and are also clinical X cancer, pancreatic the development trial second year cancer, with a important patients new antipsychotic Despite last metastatic in with
continue plan a fourth modulators. One it new promise We compound, advance XXXX. to such in to also selective evaluate the ALS. CORTXXXXXX cortisol quarter Phase of in trial in beginning We X models animal has shown of
promising size I with before, clinical said commercial I’ve Corcept’s and combines company of diverse not that any know success As do such activities.
low it the of relacorilant, know, in leading PR cortisol to not glucocorticoid a not relacorilant planned of our pregnancy, by it to of you its short, termination effects Phase XX% serious and endometrial Unlike By different hypercortisolism in for pivotal Relacorilant for cause hypokalemia, bind at a the X progesterone potassium, evaluating Korlym receptor. appear Korlym’s As trial. does discontinuation. receptor, treatment side two vaginal achieves is including Korlym, which modulator. patients does competing thickening, many to selective cause of also it successor we by trials. the Korlym hypokalemia effect mechanism, a are is not experienced Korlym, Like means cortisol with PR does Korlym, induced of effects cause bleeding.
NDA slow how and submission the delayed The in second of year. they serve we patients The Phase coupled continues in year slowed submission surge of fourth the the Cushing’s current third relacorilant’s in to pandemic depend an syndrome. slow be to know significantly persist. on of pandemic. We the our as as United in we seen in last the COVID GRACE a NDA infections our and although submitting year. with meet quarter large target abate, will pandemic unlikely and States are difficult It the the date enroll will part quarters expect when much trial of in basis the the as for has If the are NDA next Europe is addition. of GRACE rate vaccinations pace ultimately can long X of achieve duration to virulence conditions to
well We ensure glucose a strong. and to meaningful are ready in improvements effective as bleeding conditions exceptionally finish line. induced also as and drug-induced of hypertension as anxious in signs in experienced Relacorilant’s thickening GRACE and frustrating. enrollment the resume are Patients endometrial our syndrome. sites symptoms control are of The that aggressive, There results soon vaginal Cushing’s is working permit. and to Phase variety our instances as delay to to investigators were GRACE of We no relacorilant or no hypokalemia. were other take X
controlled adrenal poor. whose Our adrenal experience type of this GRADIENT by but are often Cushing’s syndrome with in relacorilant Cushing’s a in Patients decline, hyperplasia. studying patients study patients rapid an etiology less caused with first or patients this X syndrome with syndrome. of outcomes trial of is Cushing’s their relacorilant second ultimately Phase syndrome, in effects is the GRADIENT, Cushing’s adenoma health
of contribute treatment optimal findings expect We patients. its these the will to
metastatic cancer As I trials pancreatic in and this of year. the produce data first mentioned, our metastatic will half ovarian in
let further, go I some Before background. me provide
three the by of than oncology XX more is Our at testing years mechanisms University program Chicago ago. investigators postulated
study which data blunt pancreatic helping we can mechanism, anti-apoptotic ovarian pre-clinical apoptosis, our suggesting reach death and full induce. first its in effect and relacorilant There apoptosis. Cortisol suppresses concerns cell cancer The the in that clinical intended are chemotherapy potential. program to chemotherapy is cortisol’s compelling evaluating is
free endpoint Phase controlled received Patients study continuous will arms. patients X us this data progression secondary with rate, Phase a disease. relacorilant has is nab-paclitaxel duration trial three including with a trial in a alone. nab-paclitaxel hope design cancer XXX The plus or trial of endpoints overall ovarian intermittent lead to and successful doses will X in We study primary is Our platinum-resistant response objective Trial’s of or survival. guide NDA. that from survival to response, either
will We in line top from study have quarter. the results this second
The with trial of study with cancer, Our of plus including data metastatic analysis response design includes a in trial’s an response receiving patients overall rate secondary disease and nab-paclitaxel. first survival, duration with relacorilant has progression-free survival. XX the planned The primary of endpoints endpoint pancreatic each patients. objective RELIANT enrollment from patient XX is
second have results also top cohort from this will line quarter. We in the
In is as tumors of immunotherapy addition plus the drug their by patients treat in usually immune inflammatory effects the and reduces and in why excess Cushing’s the suppressing September, cortisol system, are syndrome, excess PD-X immune Xb checkpoint cortisols cortisol. KEYTRUDA monotherapy blunting inflammation patients. is immune with cancer rarely synthetic lethal which the inhibitor and Phase advanced label These apoptosis, effective effects we cortisol cancer open a auto produce suffer patients also tumors. combination. the pembrolizumab to suppresses also relacorilant may In intended whose pembrolizumab, in Merck’s system, activation cortisol Unfortunately solid believe patients We disorders. effectiveness of counteract of in to initiated used quickly these the trial an with diminishes adrenal adrenal which
to evaluating to its syndrome is these allow induced suppression reversing patients effect. killing trial cortisol with Cushing’s pembrolizumab cancer also full achieve immune by relacorilant treat by the activity of cortisol Our excess and effects reducing
this and preclinical AACR Our biomarker data clinical present ASCO meetings year’s supporting our posters at and hypothesis.
at is at the progression-free overall United You review to objective response enroll this XX them secondary endpoints, with in duration of can website. five response our plan States. tab and including trial survival, and Research endpoint patients survival. Primary the in of rate sites Pipeline/Publications We
tumor concerns androgen pathway. receptor growth treated tumors we to eventually androgen with surgeon growth patients a widely with patients with third stimulate The studying, reason ability stimulation prescribed cortisol’s of prostate enzalutamide activity stimulation to is castration-resistant in are as Cortisol cancer. their major mechanism the disease. switched a cortisol experience Pride antagonist
will that is close therapy tumor modulator a adding escape androgen cortisol hypothesis deprivation route. Our this to
dose controlled cortisol exicorilant with on shown or third diseases advancing conducting expect preclinical for larger dose studies. in X% XXX a trial identify brief treatment conclude a with opened The of controlled milligrams milligrams a a to of U.S. and miricorilant reverses NASH placebo our a participants States. serious the to Phase quarter with combined selective fatty of for regimen this are a of patients modulator trial selective that weeks. We second has liver Study NASH. December, at Phase models, miricorilant Xb enzalutamide patients planned In enrollment XXX United of a two disease will daily population. for XX castration-resistant our of miricorilant cortisol X fibrosis, miricorilant a disorder and or with and modulator cancer where trial has In prostate patients in study precursors XX either metabolic XXX liver sites promise animal clinical year. prevents I in program receive miricorilant, the in the of we in update affects and will as double-blind of suitable placebo
gain, Lilly’s disorder. such In disorder United serious illnesses anti-psychotic as bipolar a olanzapine, miricorilant to and medications, drug Risperdal treatment and evaluating J&J’s induced take Risperdal, X as million the people treat States depression. as weight and anti-psychotic such schizophrenia, Eli for also We’re Zyprexa a widespread
to on While, they average is gain XX form these disease weight disturbances. their are price such other in years steep pounds attacks expectancy drugs Patients strokes. part a rapid metabolic decreased and exact excess than as can in life events, gain, of very XX the and cardiovascular due effective, and more heart and sustained by cardiovascular
the a in these which of double-blind Two co-administration cortisol active use We these mifepristone, Korlym. adverse controlled dangerous trials modulator completed ingredient clinical in healthy have placebo in subjects reduces trials three of effects.
obesity either in placebo. received ingredient which were who XXX participants Results and Miricorilant therapy in than or be this for XXXX. Korlym XXX use. less and active XXXX in the significantly and promising. is advanced days. disorder. in olanzapine placebo who shares pill abortion miricorilant those Unfortunately, were Our prevalent miricorilant, miricorilant’s trial of journals for the cannot received and can advances XX first healthy be for with that subjects pill XX weight trial a gained published abortion the for results positive miricorilant such advanced disorder statistically received this milligrams milligrams Study of In not
triglycerides the a liver markers in to plan at that smaller exhibited in increase the they publish olanzapine addition, ALT, of damage We this presenting AST liver and onset and this therapy. a paper In of rise enzymes, results of study later the year.
trial to weight controlled gain, milligrams anti-psychotic disorder continue schizophrenia is States. weeks. is bipolar GRATITUDE Our Phase weight XXX placebo double-blind placebo induced patients. conducted enroll anti-psychotic in whether XXX of anti-psychotic can either centers established evaluating for miricorilant miricorilant medication, with reverse in The will being GRATITUDE of of or induced dose the XX or gain. trials recent XX receive in patients at to addition their United miricorilant X
stronger United is examined. Our The induced with it XXX GRATITUDE schizophrenia COVID in of primary Corcept pandemic Other XX centers patients endpoint a weeks. treatment will States. XXXX, conducted GRATITUDE in measures financially, of in anti-psychotic be be to weight. placebo we legally miricorilant a milligrams either miricorilant or is on XX of most as clinically. did metabolic companies. X important effect as in XXX testing real both the dose had milligrams will XXX anti-psychotic Nonetheless, study studies every addition will the on body In activity also for respect longstanding enter reduction XXXX medication, and or in at established their receive weight X for gain.
and net balance affected by increased Although the our results financial significantly. were revenue, our cash pandemic, income
growth conditions further as expect improve. We pandemic
XXXX guidance $XXX to million. $XXX revenue Our million is for
new patients all Phase slowed especially important those and that improved. slow X in the were of life-threatening. and existing as treatment cohort with X of delayed of valuable progress. of ago the is time metastatic enrollment completed to continue our in Cushing’s trials to has down Phase our once diseases metastatic relacorilant collect both enrollment programs pandemic clinical said, our XX Our acutely syndrome. for pancreatic not trial studying in NDA pace some ovarian We target and This That and RELIANT, The add data. date advanced first significantly, are our of our all we submitting patients relacorilant’s trials short accelerate plus enrollment also with cancer And for a in condition them substantial expect of nab-paclitaxel cancer. patients made in trials Five trials started. being patient
have cancer will and these trials cancer. of treat with the planned. We our Xb of cortisol Phase to relacorilant in point the Enrollment patients with from with PD-X both to year check and as excess. of Phase adrenal this second expect data to trial castration-resistant enzalutamide in a patients we of half first inhibitor in is advance to this and In trial with advanced underway pembrolizumab optimum quarter exicorilant the prostate year, combination a dose third X select controlled combined
underway Finally, and two, in GRATITUDE NASH one patients questions. in double-blind metabolic weight disorders, and in GRATITUDE anti-psychotic X and placebo studies patients induced enrollment patients three here for with with controlled X is I’ll Phase with stop gain.
